Physician profile
Robert A Armbruster
NPI 1174728893
$7,065.21
in general payments reported to CMS, 2019-2025
51 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $727 · 2021: $713 · 2022: $518 · 2023: $937 · 2024: $1,755 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,497 · Debt Forgiveness: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,497.48 |
| Debt Forgiveness | $394.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,029.31 | 2019-2025 | |
| Abbott Laboratories | $942.36 | 2019-2025 | Gallant, Jot Dx, Amplatzer Amulet |
| Angiodynamics, INC. | $598.88 | 2024-2025 | Angiodynamics, Auryon Laser System 100-120 Vac |
| Abiomed | $411.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $365.04 | 2019-2025 | Farxiga |
| Amgen INC. | $341.95 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $334.27 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.07 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $222.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $214.14 | 2021-2025 | Verquvo, Capvaxive |
| Penumbra, INC. | $204.82 | 2019 | |
| Novo Nordisk INC | $204.04 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $168.43 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $128.70 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $125.43 | 2019-2025 | Eliquis |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Armbruster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.